These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21803103)

  • 1. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines.
    Wiggan O; Livengood JA; Silengo SJ; Kinney RM; Osorio JE; Huang CY; Stinchcomb DT
    Vaccine; 2011 Oct; 29(43):7456-62. PubMed ID: 21803103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
    Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
    J Virol; 2020 May; 94(10):. PubMed ID: 32132233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
    Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
    Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.
    Pletnev AG; Claire MS; Elkins R; Speicher J; Murphy BR; Chanock RM
    Virology; 2003 Sep; 314(1):190-5. PubMed ID: 14517072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A spray freeze dried micropellet based formulation proof-of-concept for a yellow fever vaccine candidate.
    Clénet D; Hourquet V; Woinet B; Ponceblanc H; Vangelisti M
    Eur J Pharm Biopharm; 2019 Sep; 142():334-343. PubMed ID: 31306751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate.
    Patel A; Erb SM; Strange L; Shukla RS; Kumru OS; Smith L; Nelson P; Joshi SB; Livengood JA; Volkin DB
    Vaccine; 2018 May; 36(22):3169-3179. PubMed ID: 28506515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
    Qiao M; Shaw D; Forrat R; Wartel-Tram A; Lang J
    Am J Trop Med Hyg; 2011 Oct; 85(4):724-31. PubMed ID: 21976579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
    Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP
    J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavivirus-induced antibody cross-reactivity.
    Mansfield KL; Horton DL; Johnson N; Li L; Barrett ADT; Smith DJ; Galbraith SE; Solomon T; Fooks AR
    J Gen Virol; 2011 Dec; 92(Pt 12):2821-2829. PubMed ID: 21900425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.
    Kumru OS; Saleh-Birdjandi S; Antunez LR; Sayeed E; Robinson D; van den Worm S; Diemer GS; Perez W; Caposio P; Früh K; Joshi SB; Volkin DB
    Vaccine; 2019 Oct; 37(44):6696-6706. PubMed ID: 31548012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vector live-virus vaccines: West Nile virus vaccine development.
    Arroyo J; Miller CA; Catalan J; Monath TP
    Trends Mol Med; 2001 Aug; 7(8):350-4. PubMed ID: 11516995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.